On schedule, Biomarin Pharmaceutical Inc. this week finished off the rolling new drug application (NDA) for exon 51-skipping drisapersen to treat Duchenne muscular dystrophy (DMD), situating the firm a few months ahead of Sarepta Therapeutics Inc. with eteplirsen, another exon 51 DMD therapy.